Bio-Rad Laboratories, Inc. (BIO)
NYSE: BIO · Real-Time Price · USD
242.77
-6.97 (-2.79%)
Apr 25, 2025, 4:00 PM EDT - Market closed
Bio-Rad Laboratories Stock Forecast
Stock Price Forecast
The 4 analysts with 12-month price forecasts for Bio-Rad Laboratories stock have an average target of 396.5, with a low estimate of 270 and a high estimate of 481. The average target predicts an increase of 63.32% from the current stock price of 242.77.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Bio-Rad Laboratories stock from 4 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
Rating | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 |
---|---|---|---|---|---|---|
Strong Buy | 2 | 2 | 2 | 2 | 2 | 2 |
Buy | 1 | 1 | 1 | 1 | 1 | 1 |
Hold | 1 | 1 | 1 | 1 | 1 | 1 |
Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Total | 4 | 4 | 4 | 4 | 4 | 4 |
Latest Forecasts
Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
---|---|---|---|---|---|---|---|
Wells Fargo | Wells Fargo | Hold Maintains $320 → $270 | Hold | Maintains | $320 → $270 | +11.22% | Apr 17, 2025 |
Wells Fargo | Wells Fargo | Hold Maintains $360 → $345 | Hold | Maintains | $360 → $345 | +42.11% | Feb 12, 2025 |
RBC Capital | RBC Capital | Buy Reiterates $481 | Buy | Reiterates | $481 | +98.13% | Jan 14, 2025 |
RBC Capital | RBC Capital | Buy Maintains $369 → $481 | Buy | Maintains | $369 → $481 | +98.13% | Dec 9, 2024 |
Citigroup | Citigroup | Strong Buy Maintains $400 → $450 | Strong Buy | Maintains | $400 → $450 | +85.36% | Oct 31, 2024 |
Financial Forecast
Revenue This Year
2.59B
from 2.57B
Increased by 0.88%
Revenue Next Year
2.70B
from 2.59B
Increased by 4.44%
EPS This Year
9.73
from -65.36
EPS Next Year
11.34
from 9.73
Increased by 16.47%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
Revenue | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|
High | 2.8B | 2.9B | 3.0B | |
Avg | 2.6B | 2.7B | 2.8B | |
Low | 2.5B | 2.6B | 2.6B |
Revenue Growth
Revenue Growth | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|
High | 7.7% | 10.1% | 10.4% | |
Avg | 0.9% | 4.4% | 4.3% | |
Low | -3.4% | -1.3% | -2.1% |
EPS Forecast
EPS | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|
High | 10.76 | 12.76 | 14.18 | |
Avg | 9.73 | 11.34 | 12.21 | |
Low | 8.43 | 9.21 | 10.17 |
EPS Growth
EPS Growth | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|
High | - | 31.1% | 25.0% | |
Avg | - | 16.5% | 7.7% | |
Low | - | -5.4% | -10.3% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.